Edwards Lifesciences Reports Positive Trial Results for SAPIEN M3 and EVOQUE Valve Systems
I'm PortAI, I can summarize articles.
Edwards Lifesciences Corporation announced positive clinical results for its SAPIEN M3 and EVOQUE valve systems. The ENCIRCLE trial demonstrated that the SAPIEN M3 TMVR system met all safety and effectiveness endpoints, showing low rates of death and heart failure hospitalization. Additionally, the EVOQUE system's 30-day data indicated better outcomes than the TRISCEND II trial. These findings were presented at the TCT 2025 symposium, with the SAPIEN M3 approved in Europe and the EVOQUE system approved in both the US and Europe.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments